148 related articles for article (PubMed ID: 36536019)
1. Controlled attenuation parameter-insulin resistance (CIR) score to predict non-alcoholic steatohepatitis.
Macias J; Parra-Membrives P; Sosa-Moreno F; Rincon P; Martinez-Baena D; Fernandez-Fuertes M; Lorente-Herce JM; Martinez RC; Jimenez-Riera G; Corma-Gomez A; Gonzalez-Serna A; Pineda JA; Real LM
Sci Rep; 2022 Dec; 12(1):21897. PubMed ID: 36536019
[TBL] [Abstract][Full Text] [Related]
2. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
[TBL] [Abstract][Full Text] [Related]
3. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH
J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876
[TBL] [Abstract][Full Text] [Related]
5. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
8. FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients.
Mohammed MA; Omar NM; Mohammed SA; Amin AM; Gad DF
Pak J Biol Sci; 2019 Jan; 22(10):457-466. PubMed ID: 31930835
[TBL] [Abstract][Full Text] [Related]
9. How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis?
Trowell J; Alukal J; Zhang T; Liu L; Maheshwari A; Yoo HY; Thuluvath PJ
Dig Dis Sci; 2021 Apr; 66(4):1297-1305. PubMed ID: 32337667
[TBL] [Abstract][Full Text] [Related]
10. Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis.
Lee JI; Lee HW; Lee KS
World J Gastroenterol; 2019 Sep; 25(33):4959-4969. PubMed ID: 31543686
[TBL] [Abstract][Full Text] [Related]
11. Novel multi-parametric diagnosis of non-alcoholic fatty liver disease using ultrasonography, body mass index, and Fib-4 index.
Funada K; Kusano Y; Gyotoku Y; Shirahashi R; Suda T; Tamano M
World J Gastroenterol; 2023 Jun; 29(23):3703-3714. PubMed ID: 37398885
[TBL] [Abstract][Full Text] [Related]
12. Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection.
Benmassaoud A; Ghali P; Cox J; Wong P; Szabo J; Deschenes M; Osikowicz M; Lebouche B; Klein MB; Sebastiani G
PLoS One; 2018; 13(1):e0191985. PubMed ID: 29381754
[TBL] [Abstract][Full Text] [Related]
13. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
Harrison SA; Ratziu V; Boursier J; Francque S; Bedossa P; Majd Z; Cordonnier G; Sudrik FB; Darteil R; Liebe R; Magnanensi J; Hajji Y; Brozek J; Roudot A; Staels B; Hum DW; Megnien SJ; Hosmane S; Dam N; Chaumat P; Hanf R; Anstee QM; Sanyal AJ
Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):970-985. PubMed ID: 32763196
[TBL] [Abstract][Full Text] [Related]
14. Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease.
Lee HW; Park SY; Kim SU; Jang JY; Park H; Kim JK; Lee CK; Chon YE; Han KH
PLoS One; 2016; 11(6):e0157358. PubMed ID: 27284700
[TBL] [Abstract][Full Text] [Related]
15. Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement.
Karlas T; Petroff D; Sasso M; Fan JG; Mi YQ; de Lédinghen V; Kumar M; Lupsor-Platon M; Han KH; Cardoso AC; Ferraioli G; Chan WK; Wong VW; Myers RP; Chayama K; Friedrich-Rust M; Beaugrand M; Shen F; Hiriart JB; Sarin SK; Badea R; Lee HW; Marcellin P; Filice C; Mahadeva S; Wong GL; Crotty P; Masaki K; Bojunga J; Bedossa P; Keim V; Wiegand J
Aliment Pharmacol Ther; 2018 Apr; 47(7):989-1000. PubMed ID: 29446106
[TBL] [Abstract][Full Text] [Related]
16. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ;
PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375
[TBL] [Abstract][Full Text] [Related]
17. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort.
Imajo K; Tetlow L; Dennis A; Shumbayawonda E; Mouchti S; Kendall TJ; Fryer E; Yamanaka S; Honda Y; Kessoku T; Ogawa Y; Yoneda M; Saito S; Kelly C; Kelly MD; Banerjee R; Nakajima A
World J Gastroenterol; 2021 Feb; 27(7):609-623. PubMed ID: 33642832
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound and FibroScan
Salmi A; di Filippo L; Ferrari C; Frara S; Giustina A
Endocrine; 2022 Nov; 78(2):262-269. PubMed ID: 35980569
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.
Younes R; Rosso C; Petta S; Cucco M; Marietti M; Caviglia GP; Ciancio A; Abate ML; Cammà C; Smedile A; Craxì A; Saracco GM; Bugianesi E
Liver Int; 2018 Apr; 38(4):715-723. PubMed ID: 29028281
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity.
Pavlides M; Banerjee R; Tunnicliffe EM; Kelly C; Collier J; Wang LM; Fleming KA; Cobbold JF; Robson MD; Neubauer S; Barnes E
Liver Int; 2017 Jul; 37(7):1065-1073. PubMed ID: 27778429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
